Follistatin (FST-344): The Myostatin Inhibitor Explained
How follistatin blocks myostatin and activin A, what the gene-therapy trials actually show, and why it is not a sellable research peptide.
Follistatin comes up constantly in muscle-research and anti-aging discussions, usually described as the compound that "blocks myostatin" and unlocks dramatic muscle growth. The mechanism is real and well documented. What is much less understood is how that muscle growth has actually been produced in humans: not by an injectable peptide, but by a single physician-administered dose of viral gene therapy inside a clinical trial. This article explains follistatin's biology, walks through the real trial data, and is honest about why peptidesdirect.io does not sell it in any form.
TL;DR: What follistatin is and why we don't sell it
Follistatin is a naturally occurring glycoprotein that neutralizes myostatin and activin A, two TGF-beta family proteins that normally hold back muscle growth. Every documented human muscle-mass gain from follistatin comes from AAV1 viral gene therapy injected directly into muscle under an FDA/EMA-regulated clinical trial, not from a self-administered peptide or protein vial (PMID 25322757, PMID 28279643). In a Becker muscular dystrophy trial, treated patients gained up to 125 meters on a 6-minute-walk test with reduced muscle fibrosis and no serious adverse events (PMID 25322757). There is no legal, human-safety-tested, injectable follistatin peptide product on the market. Recombinant follistatin sold by lab-reagent suppliers is for in-vitro cell-culture research only. Because our catalog does not include a gene-therapy product, we cover the science here and point researchers toward the GH-secretagogue peptides we do carry: sermorelin, CJC-1295 and ipamorelin.
Mechanism: how follistatin blocks myostatin and activin A
Follistatin is not a synthetic peptide drug in the way sermorelin or ipamorelin are. It is a naturally occurring glycoprotein, produced in the body across multiple tissues, whose job is to bind and neutralize two closely related signaling proteins in the TGF-beta family: myostatin (also called GDF-8) and activin A. Both of these normally act as brakes on skeletal muscle growth, sending an inhibitory signal that limits how much muscle tissue accumulates. When follistatin binds myostatin or activin A, it physically blocks them from engaging their receptor on muscle cells, and the brake comes off.
The clearest mechanistic demonstration of this comes from mouse genetics. In transgenic mice engineered to express a follistatin-derived myostatin inhibitor (a construct called FS I-I, designed to selectively block myostatin while sparing normal activin signaling), skeletal muscle mass increased by roughly 37 percent compared to normal littermates, through a combination of individual muscle fibers growing larger (hypertrophy) and new fibers forming (hyperplasia). When the same construct was bred into mdx mice, the standard mouse model of Duchenne muscular dystrophy, it also reduced the dystrophic muscle damage characteristic of that disease (PMID 17893249).
The reverse experiment confirms the same biology from the other direction. Mice engineered to have only one functional copy of the follistatin gene, and therefore reduced follistatin levels, develop smaller muscles, a shifted balance of fiber types, weaker force output and impaired muscle repair after injury. That establishes follistatin's muscle-growth effect as running specifically through its dual role as a myostatin and activin A antagonist within the broader TGF-beta signaling network, not through some unrelated pathway (PMID 20810712).
One added layer of complexity is that follistatin does not come in just one form. Different splice variants and molecular domains of the follistatin protein bind myostatin and activin A with different affinities and have different tissue-distribution and systemic-exposure profiles. Mapping work on these follistatin-type domains (FS-N, FSD1, FSD2) shows why the specific variant used matters for how selective and how systemic the effect is, and it is this mapping that underlies the choice of the FS-344 variant in the clinical gene-therapy programs discussed below (PMID 22593183).
The clinical evidence: AAV gene-therapy trials, not peptide injections
This is the part of the follistatin story that gets lost in most online discussion: every documented case of follistatin increasing muscle mass or function in a human being comes from a single physician-administered injection of a viral vector carrying the follistatin gene directly into muscle tissue, monitored under an FDA or EMA-regulated clinical trial protocol. It does not come from a self-injected peptide or protein solution.
The first human proof of concept was a Phase 1/2a trial in Becker muscular dystrophy. Six patients received AAV1.CMV.FS344, an adeno-associated viral vector carrying the follistatin-344 gene, injected bilaterally into their quadriceps muscles. On the 6-minute-walk test, a standard measure of functional mobility in muscle disease, responders improved by as much as 125 meters. Muscle biopsies after treatment showed reduced fibrosis (scarring) and larger individual muscle fiber size, and no adverse events were reported (PMID 25322757).
A second trial extended the same gene-therapy approach to sporadic inclusion body myositis, a progressive muscle-wasting disease with no approved treatment. Six patients received rAAV1.CMV.huFS344 at a dose of 6x10^11 vector genomes per kilogram, injected into both quadriceps. Over the following year, the treated group improved by an average of 56.0 meters per year on the 6-minute-walk test, compared to a 25.8 meter per year decline in a matched group of untreated patients, a statistically significant difference (p=0.01). Four of the six treated patients gained between 58 and 153 meters, and biopsies again showed reduced fibrosis and better signs of muscle regeneration (PMID 28279643).
Why the delivery method is the whole story here
Both trials used a one-time intramuscular injection of an adeno-associated viral vector (AAV1), a modified virus engineered to carry the follistatin gene into muscle cells so those cells then produce follistatin protein locally and continuously over time. This is fundamentally different from injecting a peptide or recombinant protein, which delivers a fixed dose that is cleared from the body within hours to days. Gene therapy requires an Investigational New Drug (IND) application, manufacturing of a clinical-grade viral vector, and administration by a physician in a monitored clinical setting. None of the muscle-growth results described here have ever been reproduced with a self-administered peptide, and no such trial exists.
Beyond dystrophy: the localized-hypertrophy fusion-protein approach
A separate line of research asked whether the same myostatin/activin-blocking effect could be delivered locally, without a full-body systemic exposure and without gene therapy at all. The answer was ACE-083, a follistatin-Fc fusion protein designed to act only at the injection site rather than circulating throughout the body. Structurally, ACE-083 neutralizes not just myostatin and activin A, but also activin B and GDF11, a broader net across the same inhibitory protein family.
In mouse models of two different neuromuscular diseases, Charcot-Marie-Tooth disease and Duchenne muscular dystrophy, ACE-083 produced localized muscle hypertrophy (growth confined to the injected muscle) along with measurable functional improvement, without the systemic effects that a body-wide follistatin exposure would carry (PMID 31388039). Based on this preclinical work, ACE-083 progressed into Phase 2 human trials in patients with facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease, testing whether localized muscle strengthening could translate into functional benefit for these specific muscle-wasting conditions. Development of ACE-083 was later discontinued by its sponsor.
ACE-083 is still not a follistatin peptide in any conventional sense. It is an engineered fusion protein, administered as an investigational drug in a controlled trial, and it was never marketed or available outside that trial framework.
Muscle and GH/IGF-1 relevance: two different roads to the same destination
Researchers interested in lean-mass preservation and anti-catabolic mechanisms often end up looking at follistatin specifically because its mechanism is GH-independent. Follistatin does not touch the growth hormone or IGF-1 axis at all. It works entirely by removing an inhibitory brake, neutralizing myostatin and activin A so that muscle tissue is no longer held back from growing (PMID 20810712).
This puts follistatin in a different mechanistic lane from the GH-secretagogue peptides that this site covers, which work by stimulating the pituitary gland to release more growth hormone, which in turn raises IGF-1 and drives anabolic, tissue-building signaling through an entirely separate receptor system (the GHRH receptor and the ghrelin receptor, rather than the TGF-beta receptor family that myostatin and activin use). Two different pathways, but researchers care about both because they converge on the same outcome: preserved or increased lean muscle mass, and better resistance to muscle wasting. This is also the mechanistic bridge relevant to research on GLP-1-associated muscle loss, where the interest is in anti-catabolic and lean-mass-preserving pathways generally, whether the specific mechanism runs through myostatin blockade or through GH/IGF-1 stimulation.
What the community reports
What the community reports (anecdotal, not clinical evidence)
The following is a summary of general sentiment across bodybuilding and TRT-adjacent forums (AnabolicMinds, MESO-Rx/thinksteroids, forums.steroid.com, eroids.com). None of this is clinical evidence or medical advice, and several points here are the forum posters' own cautionary warnings, not endorsements.
Sourcing and authenticity is the most repeated concern. Threads describe most research-chemical vendors as selling fake or underdosed "FST-344," with one poster citing a price near 5,000 dollars per milligram for material believed to be genuine. This lines up with a real published lab analysis that tested 17 black-market "FS344" products and found only 9 actually contained follistatin, with others containing entirely different compounds such as MGF or GHRP-2 (PMID 31758732).
Delivery-mechanism skepticism shows up repeatedly. Forum members point out, correctly, that the animal and human studies showing real muscle growth used gene-therapy or viral-vector delivery for sustained local overexpression, not a subcutaneous injection of free peptide, and several posters doubt that an injected raw peptide has the stability or half-life to reproduce those results at all.
Reported subjective effects are split. Some self-experimenters, often while stacking other compounds, describe strong, fast changes such as pronounced leanness or several pounds gained within a week. Others, including experienced MESO-Rx commenters, report no discernible effect over a full cycle and describe commercially available product as "bunk" for human muscle-building.
Logged protocols cluster around 50 to 200 micrograms per day subcutaneously for short stretches, often 10 to 11 day cycles, with cost cited more often than tolerance as the reason cycles stay short. Some posters attribute any reported gains partly to increased appetite and food intake alongside the compound rather than to the compound itself.
The most serious repeated warning concerns a real published case series: 11 bodybuilders who developed central serous chorioretinopathy, a vision-blurring or vision-loss condition, after injecting whole 1 milligram vials of follistatin-344 (PMID 32671599). Forum threads reference this case series directly as a reason to avoid high single doses.
Posters also frame FST-344 explicitly as a gray or black-market, doping-relevant substance rather than a routine research peptide, noting its place on WADA's prohibited list. Overall sentiment across these forums runs cautious to skeptical, with a smaller vocal minority still running short cycles and reporting subjective results. Separately, some SEO-style "peptide guide" sites circulate specific-sounding statistics, such as a supposed 12-week trial showing a defined kilogram range of lean-mass gain, that could not be traced to any real, indexed clinical trial and contradict the actual literature. Those figures should not be treated as genuine data.
Why we do not sell follistatin
Follistatin is not a legally available research peptide
Every documented instance of follistatin increasing human muscle mass comes from AAV1 viral gene therapy delivered under an FDA- or EMA-regulated clinical trial protocol, administered by a physician as a single injection event, not from a self-administered peptide or recombinant protein. There is no legal, over-the-counter, research-grade injectable follistatin product with any human safety data. Recombinant follistatin protein sold by lab-reagent suppliers exists solely for in-vitro and cell-culture research, and has never been studied as a self-injected human protocol. peptidesdirect.io does not sell, source or ship follistatin, FST-344 or FS-344 in any form, and this article should not be read as guidance toward obtaining it.
Follistatin also sits outside our catalog for a structural reason beyond its legal and safety status: the only clinical path that has ever produced the muscle-growth results described above is gene therapy, a category of product this shop does not carry in any form, for any target.
The research peptides we carry for the GH/muscle axis
For research into the GHRH-receptor and ghrelin-receptor pathways that drive endogenous growth hormone and IGF-1 signaling, the following peptides are available for laboratory research use:
GHRH(1-29) analog for physiological growth hormone stimulation research
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH(1-29) analog for GH/IGF-1 research. Research-grade lyophilized powder, specified purity >=99% (HPLC). Laboratory use only.
Highly selective growth hormone releaser that triggers natural GH pulses without raising cortisol or prolactin. Clean GH stimulation with minimal side effects - the most targeted growth hormone peptide available.
Growth hormone secretagogues and gonadotropins
Lean-mass research
GHRH(1-29) analog for physiological growth hormone stimulation research
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH(1-29) analog for GH/IGF-1 research. Research-grade lyophilized powder, specified purity >=99% (HPLC). Laboratory use only.
Highly selective growth hormone releaser that triggers natural GH pulses without raising cortisol or prolactin. Clean GH stimulation with minimal side effects - the most targeted growth hormone peptide available.
Sermorelin is GHRH(1-29), the shortest active fragment of natural growth-hormone-releasing hormone, and activates the GHRH receptor to produce a pulsatile, physiological GH release. CJC-1295 (the No-DAC form carried here) is a DPP-IV-resistant GHRH(1-29) analogue targeting the same receptor with a metabolically hardened structure, commonly paired with ipamorelin for synergistic GHRH/ghrelin-receptor signaling. Ipamorelin is a selective ghrelin-receptor agonist that stimulates GH release with minimal effect on cortisol or prolactin.
None of these three peptides blocks myostatin or activin A, and none is a substitute for follistatin's mechanism. They engage a completely different receptor system, the GHRH receptor and the ghrelin receptor rather than the TGF-beta receptor family, and they raise growth hormone and IGF-1 rather than removing a muscle-growth brake directly. They are relevant here only because they are the legally available, human-research-relevant tools for the GH/muscle axis that follistatin's own clinical evidence sits alongside, not because they reproduce what follistatin gene therapy does.
Questions about follistatin availability
peptidesdirect.io does not sell, source or ship follistatin, FST-344 or FS-344 under any circumstances, and cannot advise on obtaining it. Follistatin gene therapy is an investigational, physician-administered treatment available only within regulated clinical trials. For questions about follistatin availability, please consult a licensed physician or clinical-trial registry. For questions about the GH-secretagogue research peptides covered in this article, contact [email protected].
Frequently asked questions
This article is for informational and educational purposes only. All mentioned peptides are intended exclusively for laboratory research and not for human consumption. We do not sell the drug this article is about. For Research Purposes Only.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.